Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
M. Dougados, M. Revel, M.A. Khan.
Management of spondyloarthropathy.
Therapy of systemic disorders, pp. 375-406
[2.]
L. Koehler, J.G. Kuipers, H. Zeidler.
Managing seronegative spondarthritides.
Rheumatology (Oxford), 39 (2000), pp. 360-368
[3.]
S. Van der Linden, D. Van der Heijde, J. Braun, et al.
Ankylosing spondylitis..
Kelley's textbook of rheumatology, 7th ed., pp. 1125-1141
[4.]
M. Dougados, B. Dijkmans, M. Khan, W. Maksymowych, J.J. Van der Linden, J. Brandt.
Conventional treatment for ankylosing spondylitis.
Ann Rheum Dis, 61 (2002), pp. 40-50
[5.]
J. Braun, T. Pham, J. Sieper, J. Davis, S. Van der Linden, M. Dougados, et al.
International ASAS consensos statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis.
Ann Rheum Dis, 62 (2003), pp. 817-824
[6.]
Panel de expertos de la Sociedad Española de Reumatología.
Primer Documento de Consenso de la Sociedad Española de Reumatología sobre el uso de antagonistas del TNF-alfa en las espondiloartritis.
Reumatol Clin, 1 (2005), pp. 32-37
[7.]
B. Amor, M. Dougados, M. Mijiyawa.
Criteres de classification des spondyloarthropathies.
Rev Rheum Mal Ost, 57 (1990), pp. 85-89
[8.]
M. Dougados, V. Listrat, C.J. Menkes, et al.
Evaluation des criteres de spondylarthropathies d’Amor et de l’European Spondyloarthropathy Study Group (ESSG). Un etude transversale de 2228 patients.
Ann Med Interne, 141 (1991), pp. 85-89
[9.]
J. Sieper, J. Braun.
New treatement options in Ankylosing Spondylitis: a role for anti-TNF alpha therapy.
Ann Rheum Dis, 60 (2001), pp. 58-61
[10.]
B. Amor, R.S. Santos, R. Nahal, V. Listrat, M. Dougados.
Predictive factors for the longterm outcome of spondyloarthropathies.
J Rheumatol, 21 (1994), pp. 1883-1887
[11.]
R. Sanmartí.
Tratamiento médico de la espondilitis anquilosante. Antiinflamatorios no esteroideos y fármacos antirreumáticos modificadores de enfermedad.
Monografía SER. Espondiloartritis, pp. 159-170
[12.]
J. Braun, J. Sieper.
Biological therapies in the spondyloarthritides-the current state.
Rheumatology (Oxford), 43 (2004), pp. 1072-1084
[13.]
R. Treves, R. Desproges-Gotteron.
NSAIDS in ankylosing spondylitis: indications, efficacy, tolerance, prognostic incidence. La spondylarhrite ankylosante. Actualités nosologiques et thérapeutiques.
Masson, (1988),
[14.]
M. Dougados, A. Gueguen, J.P. Nakache, P. Velicitat, E.M. Veys, H. Zeidler, et al.
Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial.
Rheumatology (Oxford), 38 (1999), pp. 235-244
[15.]
B.P. Wordsworth, R.W. Ebringer, E. Coggins, S. Smith.
A double-blind cross-over trial of fenoprofen and phenylbutazone in ankylosing spondylitis.
Rheumatol Rehab, 19 (1980), pp. 260-263
[16.]
J.D. Jessop.
Double-blind study of ketoprofen and phenylbutaone in ankylosing spondylitis.
Rheumatol Rehab, (1976), pp. 37-42
[17.]
H.E. Paulus.
FDA arthritis advisory committee meeting.
Arthritis Rheum, 28 (1985), pp. 450-451
[18.]
A. Calin, J. Elswood.
A prospective nationwide cross-sectional study of NSAID usage in 1,331 patients with ankylosing spondylitis.
J Rheumatol, 17 (1990), pp. 801-803
[19.]
R. Sanmartí-Sala.
Anttinflamatorios no esteroideos y espondilartritis anquilosante.
Rev Esp Reumatol, 28 (2001), pp. 365-368
[20.]
E. Batlle-Gualda, M. Figueroa, J. Ivorra, A. Raber.
The efficacy and tolerability of aceclofenac in the treatment of patients with ankylosing spondylitis: a multicenter controlled clinical trial. Aceclofenac Indomethacin Study Group.
J Rheumatol, 23 (1996), pp. 1200-1206
[21.]
L.F. Villa Alcázar, M. De Buergo, H. Rico Lenza, E. Montull Frutos.
Aceclofenac is safe and effective as tenoxicam in the treatment of ankylosing spondylitis: a 3 month multicenter comparative trial. Spanish Study Group on aceclofenac in Ankylosing spondylitis.
J Rheumatol, 23 (1996), pp. 1194-1199
[22.]
M. Dougados, J.M. Behier, I. Jolchine, A. Calin, D. Van der Heijde, I. Olivieri, et al.
Efficacy of celecoxib, a cyclooxygenase 2-specific inibitor, in the treament of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventionl nonsteroidal antiinflamatory drug.
Arthritis Rheum, 44 (2001), pp. 180-185
[23.]
Gossec L, Van der Heijde D, Melian A, Krupa DA, James MK, Cavanaugh PF Jr, et al. The efficacy of cyclooxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis. En prensa. 2005.
[24.]
C. Bombardier, L. Laine, A. Reicin, D. Shapiro, R. Burgos-Vargas, R. Davis, et al.
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
N Engl J Med, 23 (2000), pp. 1520-1528
[25.]
F.E. Silverstein, G. Faich, J.L. Goldstein, L.S. Simon, T. Pincus, A. Whelton, et al.
Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled tria. Celecoxib Long-term Arthritis Safety Study.
JAMA, 284 (2000), pp. 1247-1255
[26.]
F. De Keyser, D. Elewaut, M. De Vos, K.D. De Vlam, C. Cuvelier, H. Mielants, et al.
Bowel inflammation and the spondyloarthropathies.
Rheumatic Dis Clin North Am, 24 (1998), pp. 785-813
[27.]
J.H. Vaile, J.B. Meddings, B.R. Yacyshyn, A.S. Russell, W.P. Maksymowych.
Bowel permeability and CD45RO expression on circulating CD20+ B cells in patients with ankylosing spondylitis and their relatives.
J Rheumatol, 26 (1999), pp. 128-135
[28.]
G. Sigthorsson, R. Crane, T. Simon, M. Hoover, H. Quan, J. Bolognese, et al.
COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin.
Gut, 47 (2000), pp. 527-532
[29.]
E. De Klerk, S.J. Van der Linden.
Complance monitoring of NSAID drug therapy in ankylosing spondyliis, experiences with an electronic monitoring device.
Br J Rheumatol, 35 (1996), pp. 60-65
[30.]
J.W. Boersma.
Retardation of ossifiction of the lumbar vertebral column in ankylosing spondylitis by means of phenylbutazone.
Scand J Rheumatol, 5 (1976), pp. 60-64
[31.]
S. Brophy, K. Mackay, A. Al-Saidi, G. Taylor, A. Calin.
The natural history of ankylosing spondylitis as defined by radiological progression.
J Rheumatol, 29 (2002), pp. 1236-1243
[32.]
A. Lussier, R. De Medicis.
Correlation between ossification and inflammation using a rat experimental model.
J Rheumatol, 11 (1983), pp. 114-117
[33.]
A. Wanders, D. Van der Heidje, R. Landewé, J.M. Behier, A. Calin, I. Olivieri, et al.
Nonsterroidal antiinflammatory drugs reduce rediographic progression in patients with an kylosing spondylitis: a randomized clinical trial.
Arthritis Reum, 52 (2005), pp. 1756-1765
Copyright © 2005. Elsevier España S.L. Barcelona
